Intarcia Therapeutics

SeaStar Medical Appoints David A. Green as Chief Financial Officer

Retrieved on: 
목요일, 1월 11, 2024
Bard (company), Death, Duff, Duff & Phelps, Therapy, State university system, Intarcia Therapeutics, State, CFO, Certified Public Accountant, University, Interim management, MBA, Interim, Growth, Pharmaceutical industry

Green as Chief Financial Officer, effective January 10, 2024.

Key Points: 
  • Green as Chief Financial Officer, effective January 10, 2024.
  • Caryl Baron, who has served as Interim CFO since October 2022, will continue with SeaStar Medical as Vice President of Finance.
  • “We welcome David to our executive team at this critical time as we prepare for our first commercial launch for the Selected Cytopheretic Device Pediatric (SCD-PED) later this quarter,” said Eric Schlorff, CEO of SeaStar Medical.
  • Earlier, he was Chief Accounting Officer at Intarcia Therapeutics, a commercial-stage biopharmaceutical company; CFO of Catheter Connections, a commercial-stage medical device company acquired by Merit Medical; and CFO of Specialized Health Products International, a publicly traded medical device company acquired by C.R.

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Retrieved on: 
월요일, 11월 20, 2023
Research, Therapy, Dartmouth College, Disease, History, Patient, Investment, Bain Capital, C4, Fidelity Investments, Sanofi–Translate Bio COVID-19 vaccine, Physician, Intarcia Therapeutics, CCCC, Management, Sanofi

WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors.

Key Points: 
  • WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors.
  • Mr. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance.
  • “We are thrilled to welcome Owen to the board of directors and leverage his experience across capital markets and pivotal business development opportunities,” said Bruce Downey, chairman of the board of directors of C4 Therapeutics.
  • “I look forward to working with the board of directors and management team to capitalize on the company’s scientific prowess to the benefit of patients and shareholders alike.”

Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

Retrieved on: 
월요일, 9월 18, 2023
Endocrinology, University, Atlas Venture, Diabetes, Internal medicine, CSO, Intarcia Therapeutics, Cardiovascular disease, Atlas, Head, Research, CMO, Bristol Myers Squibb, Apixaban, Harvard Medical School, Metabolism, Washington University School of Medicine, Faculty, Growth, BMS, Therapy, Pharmaceutical industry, Medical device, Verve, Medicine

Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO.

Key Points: 
  • Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO.
  • “We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company,” said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve.
  • Verve’s tremendous progress over the last five years has been made possible by Andrew’s significant contributions in his joint role.
  • Under his leadership, several new medicines achieved successful marketing authorization, including Eliquis® (apixaban), Farxiga® (dapagliflozin), Onglyza® (saxagliptin) and Myalept® (metreleptin).

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs

Retrieved on: 
월요일, 9월 18, 2023
Yee, Medical Affairs Bureau, Senior, Harvard T.H. Chan School of Public Health, Intarcia Therapeutics, Biotechnology, AB, Boston, Harvard College, OSA, Harvard University, Harvard Medical School, Genzyme, Public health, AstraZeneca, Vertex Pharmaceuticals, Hospital, MPH, Health administration, Therapy, Obstructive sleep apnea, Flexion Therapeutics, Pharmaceutical industry, MD

Dr. Yee has more than 25 years of leadership experience at leading biotechnology, pharmaceutical, and healthcare technology companies, and at a major academic medical center.

Key Points: 
  • Dr. Yee has more than 25 years of leadership experience at leading biotechnology, pharmaceutical, and healthcare technology companies, and at a major academic medical center.
  • Prior to joining Apnimed, Dr. Yee served as Chief Medical Officer at Sobi North America.
  • Dr. Yee earned an MD from Harvard Medical School, an MPH in Health Care Management from the Harvard T.H.
  • Prior to his career in industry, Dr. Yee held leadership roles at Boston Children’s Hospital and was a faculty member at Harvard Medical School.

i2o Therapeutics Names Kurt Graves Chairman and CEO, Announces Corporate Updates

Retrieved on: 
월요일, 8월 28, 2023
Health, Diabetes, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Executive, Obesity, Prevalence, Harvard University, The Conference Board, Intarcia Therapeutics, Disability, EVP, Policy, Intarsia, PYY, Ionic liquid, IP, Glucagon, Medication, Novartis, Acquisition, Omeprazole, Vertex Pharmaceuticals, ITCA, Merck, Commercial, Therapy, Lancet, Death, House of Medici, Society, GI, Peptide, Disease, Corporate development, Pharmaceutical industry

i2o Therapeutics, Inc. today announced the appointment of Kurt Graves as Chairman, President and CEO.

Key Points: 
  • i2o Therapeutics, Inc. today announced the appointment of Kurt Graves as Chairman, President and CEO.
  • Mr. Graves succeeds i2o co-founder and CEO Ravi Srinivasan, Ph.D., who is pursuing other leadership opportunities within the life sciences field.
  • He has previously served as Chairman, President and CEO of Intarcia Therapeutics, former Chairman of Radius Health, former Executive Chairman of i2o Therapeutics, and as a Board member at Achillion Pharmaceuticals until it was acquired, and at Seres Health.
  • Previously, Mr. Graves served as EVP, Head of Corporate Development, Strategic Drug Development and Program Management and Head of Commercial at Vertex Pharmaceuticals.

FibroGen Announces Leadership Transition

Retrieved on: 
화요일, 7월 25, 2023
Interim, Culture, Intarcia Therapeutics, Conterno, Intarsia, Washington University in St. Louis, Science, Lilly, Patient, SAN, Biology, Growth, Therapy, Global marketing, Eli Lilly and Company, Management, Nursing, Pharmaceutical industry, Roxadustat

SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the appointment of Thane Wettig as the Company’s interim Chief Executive Officer effective as of July 23, 2023. Mr. Wettig has served as FibroGen’s Chief Commercial Officer and a key member of the senior leadership team since June 2020. Mr. Wettig succeeds Chief Executive Officer Enrique Conterno, who resigned due to personal reasons. To support Mr. Wettig, Mr. Conterno will serve as a Special Advisor to the CEO during a transition period.

Key Points: 
  • Mr. Wettig has served as FibroGen’s Chief Commercial Officer and a key member of the senior leadership team since June 2020.
  • To support Mr. Wettig, Mr. Conterno will serve as a Special Advisor to the CEO during a transition period.
  • “We have a strong cash position, and have built a great team at FibroGen, including a highly experienced and collaborative leadership team.
  • Mr. Wettig began his career at Lilly in 1990 and served in multiple leadership roles of increasing responsibility during his Lilly tenure.

Ocelot Bio Appoints Lise Kjems, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
화요일, 4월 18, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Endocrinology, University, Therapy, Liver disease, Bio, Intarcia Therapeutics, Physiology, Multimedia, Biliary atresia, ESLD, Cirrhosis, EMA, Acute kidney injury, Hepatorenal syndrome, Novartis, Patient, Ocelot, Novo Nordisk, Ascites, Johnson & Johnson, Alagille syndrome, FDA, Cyclo, PFIC, Autoimmunity, Safety, Ionis Pharmaceuticals, Pharmaceutical industry

Dr. Kjems succeeds founding chief scientific & medical officer, Stan Bukofzer, M.D., who will provide continued guidance to Ocelot Bio as a Strategic Advisor.

Key Points: 
  • Dr. Kjems succeeds founding chief scientific & medical officer, Stan Bukofzer, M.D., who will provide continued guidance to Ocelot Bio as a Strategic Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20230418005491/en/
    Ocelot Bio Appoints Lise Kjems, M.D., Ph.D., as Chief Medical Officer (Photo: Business Wire)
    “Dr.
  • “I am thrilled to welcome Dr. Kjems to the role of chief medical officer and am confident that her depth of experience leading successful clinical programs will add incredible value to the Ocelot Bio team.
  • Prior to joining Ocelot Bio, Dr. Kjems was the chief medical officer at Cyclo Therapeutics where she led its global program evaluating Trappsol® Cyclo™ in Alzheimer’s and rare disease.

New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy

Retrieved on: 
수요일, 1월 4, 2023
Investment banking, Lead, Economics, Datamonitor, Medication, Therapy, Patent monetization, LP, Corporation, Operation, MBA, Columbia Business School, Growth, ICAV, Dartmouth College, Bain Capital, Entrepreneurship, Investment, University, Health care, CPP Investment Board, Intarcia Therapeutics, Sanofi–Translate Bio COVID-19 vaccine, Strategic planning, DNAnexus, Sale, Management, History, Sanofi, Finance

EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Jim Neal has retired as Chief Executive Officer and two finance and biotechnology industry veterans have joined in newly created executive leadership roles to drive the Company’s next phase of accelerated growth.  Mr. Neal has resigned as a director of the company effective January 1, 2023.  The Board of Directors has appointed Owen Hughes as Executive Chairman of the Board and Brad Sitko as XOMA’s Chief Investment Officer.

Key Points: 
  • The Board of Directors has appointed Owen Hughes as Executive Chairman of the Board and Brad Sitko as XOMA’s Chief Investment Officer.
  • “The Board recognized XOMA’s growth would be best served with a leadership structure that reflects the unique demands of the Company’s royalty aggregator strategy.
  • The Board is fully committed to supporting their efforts as they accelerate the expansion of XOMA’s royalty portfolio,” stated W. Denman (Denny) Van Ness, Lead Independent Director of XOMA.
  • Mr. Sitko brings deep expertise in royalty monetizations having been involved with the asset class for over 15 years as an investor, investment banker, and strategy consultant.

Ikena Oncology Appoints Owen Hughes as Board Chair

Retrieved on: 
월요일, 12월 19, 2022
Corporate development, Bain Capital, Science, Morgan Stanley, Therapy, Sanofi, Research, Fidelity Investments, Acquisition, Intarcia Therapeutics, Hughes, Wall Street, Hippopotamus, Investment, Sanofi–Translate Bio COVID-19 vaccine, Doctor of Philosophy, Sale, Management

BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that after a successful 4-year tenure as Chairman of the Board of Directors, Ron Renaud will be stepping down from the role to focus on his new position as Managing Director at Bain Capital Life Sciences. Owen Hughes has been appointed as a new board member and will be assuming the role of Chair of the Board of Directors, effective December 15, 2022.

Key Points: 
  • Owen Hughes has been appointed as a new board member and will be assuming the role of Chair of the Board of Directors, effective December 15, 2022.
  • “On behalf of the Board of Directors and the entire company, I am thrilled to welcome Owen to our board.
  • Owen is a perfect addition to the board and his experience and values will continue to support Ikena’s trajectory.”
    Hughes, who serves as Chief Executive Officer of Sail Bio and Co-Founder of Cullinan Oncology, will join as Chairman of the Board of Directors.
  • “I am looking forward to working together to advance and grow Ikena’s pipeline and redefine the targeted oncology landscape.”

RenovoRx Appoints James Ahlers as Chief Financial Officer

Retrieved on: 
화요일, 7월 19, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Titan, American Institute, Research, University, Terminology, Intellectual property, Neoplasm, LAPC, Cancer, Patient, Controller, CPA, Security (finance), Nasdaq, Association, Cholangiocarcinoma, Safety, U.S. Securities and Exchange Commission, Certified Public Accountant, Pancreatic cancer, Securities Exchange Act of 1934, Forward-looking statement, Intarcia Therapeutics, Technology, Duquesne University, LLC, Goal, Initial public offering, Securities Act of 1933, Industry, COVID-19, Commonwealth, Growth, Bachelor of Science in Human Biology, Â, Nature, Therapy, CFO, FDA, List of life sciences, Management, Pharmaceutical industry, Science

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx.

Key Points: 
  • RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx.
  • Mr. Ahlers replaces Christopher J. Lehman, who joined RenovoRx in connection with its initial public offering and is leaving to pursue a new business opportunity.
  • He served as Chief Financial Officer of Intarcia Therapeutics, Inc. and has held senior finance roles with Titan Pharmaceuticals, Inc. and Ansan Pharmaceuticals Inc. Additionally, Mr. Ahlers has provided consulting services to multiple public and private life science companies.
  • On behalf of our team, we thank Chris for his contributions, said Shaun Bagai, Chief Executive Officer of RenovoRx.